0 12

Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study

Authors
 Kyung Hee Lee, Min Kyoung Kim, Yeol Hong Kim, Baek Yeol Ryoo, Ho Yeong Lim, Hong Suk Song, Hoon Kyo Kim  ;  Myung Ah Lee  ;  Seock Ah Im  ;  Heung Moon Chang  ;  Jae Yong Cho  ;  Dae Young Zang  ;  Bong Seog Kim  ;  Jun Suk Kim 
Citation
 Cancer Chemotherapy and Pharmacology, Vol.64(2) : 317-325, 2009 
Journal Title
 Cancer Chemotherapy and Pharmacology 
ISSN
 0344-5704 
Issue Date
2009
MeSH
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Female ; Follow-Up Studies ; Humans ; Liver Neoplasms/drug therapy* ; Liver Neoplasms/secondary ; Lung Neoplasms/drug therapy* ; Lung Neoplasms/secondary ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Pancreatic Neoplasms/drug therapy* ; Pancreatic Neoplasms/pathology ; Prognosis ; Quality of Life ; Survival Rate ; Treatment Outcome ; Young Adult
Abstract
PURPOSE: Gemcitabine is the only drug approved for single-agent therapy in advanced pancreatic carcinoma (APC). Gemcitabine-based combination chemotherapy has not yet shown promising results. METHODS: This multicenter phase II study enrolled previously untreated patients with locally advanced and/or metastatic pancreatic adenocarcinoma. Patients received 1,000 mg/m(2) gemcitabine, 100-min infusion, day 1 and 100 mg/m(2) oxaliplatin, 2-h infusion, day 2; q2w. The primary end point was response rate (RR). RESULTS: Thirteen study centers enrolled 48 eligible patients of which 44 were evaluable. The RR, median overall survival, and median time to progression were 18.2%, 9.4 and 5.6 months, respectively. Sixteen patients (36.4%) experienced clinical benefit. The global quality of life scores improved by 11.71. Grade 3/4 peripheral sensory neuropathy was noted (2.1%), while the most common hematologic toxicity was anemia (grade 3/4, 6.3%). CONCLUSIONS: Gemcitabine and oxaliplatin combination chemotherapy showed a promising activity in APC patients and was well tolerated.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/165776
DOI
10.1007/s00280-008-0873-9
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
조재용(Cho, Jae Yong) ORCID logo https://orcid.org/0000-0002-0926-1819
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse